Champix

Designed to manage nicotine addiction and indicated to support smoking cessation by mitigating cravings and relieving withdrawal discomfort during treatment.

Strengths: 0.5 · 1mg

Medicine details

Therapeutic class

Smoking Cessation Aid

Pharmacological class

Nicotinic Receptor Partial Agonist

Contraindications

hypersensitivity to varenicline

Precautions and warnings

monitor for neuropsychiatric symptoms; caution with alcohol intake

Minor side effects

nausea; insomnia

Moderate side effects

vivid dreams; headache

Dosage forms

Film-coated tablet

Administration route

Oral use

Prescription status

POM

Manufacturer

Pfizer

Onset Time

1–2 weeks

Duration

12 weeks

Storage instructions

Store below 30°C.

Drug interactions

nicotine replacement therapy

Age restrictions

18 years and older.

Pregnancy and breastfeeding

Not recommended during pregnancy.

Serious side effects

suicidal ideation — requires immediate medical attention; depression — requires immediate medical attention

Patient summary

Designed to manage nicotine addiction and indicated to support smoking cessation by mitigating cravings and relieving withdrawal discomfort during treatment.

Mechanism of action

Varenicline acts as a partial agonist at alpha-4-beta-2 nicotinic acetylcholine receptors. It stimulates these receptors to relieve nicotine withdrawal cravings while simultaneously blocking nicotine from binding to them, which reduces the reinforcing effects of smoking.

Champix

Designed to manage nicotine addiction and indicated to support smoking cessation by mitigating cravings and relieving withdrawal discomfort during treatment.

Editorial Notes

  • Active ingredient(s): Varenicline
  • Listed indication(s): Smoking Cessation

Usually available as

  • 60 tablets - 0.5 mg996-0-5-mg-12588
  • 30 tablets - 1 mg996-1-mg-12579